These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36878996)

  • 21. Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial.
    Grodin EN; Nieto SJ; Meredith LR; Burnette E; O'Neill J; Alger J; London ED; Miotto K; Evans CJ; Irwin MR; Ray LA
    Addict Biol; 2022 Jul; 27(4):e13182. PubMed ID: 35754106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents.
    Gray KM; Carpenter MJ; Baker NL; DeSantis SM; Kryway E; Hartwell KJ; McRae-Clark AL; Brady KT
    Am J Psychiatry; 2012 Aug; 169(8):805-12. PubMed ID: 22706327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence.
    Prisciandaro JJ; Tolliver BK; Prescot AP; Brenner HM; Renshaw PF; Brown TR; Anton RF
    Transl Psychiatry; 2017 Jul; 7(7):e1163. PubMed ID: 28675386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low Pretreatment Impulsivity and High Medication Adherence Increase the Odds of Abstinence in a Trial of N-Acetylcysteine in Adolescents with Cannabis Use Disorder.
    Bentzley JP; Tomko RL; Gray KM
    J Subst Abuse Treat; 2016 Apr; 63():72-7. PubMed ID: 26827257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perturbation of the glutamate-glutamine system in alcohol dependence and remission.
    Thoma R; Mullins P; Ruhl D; Monnig M; Yeo RA; Caprihan A; Bogenschutz M; Lysne P; Tonigan S; Kalyanam R; Gasparovic C
    Neuropsychopharmacology; 2011 Jun; 36(7):1359-65. PubMed ID: 21389979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.
    Falk DE; Ryan ML; Fertig JB; Devine EG; Cruz R; Brown ES; Burns H; Salloum IM; Newport DJ; Mendelson J; Galloway G; Kampman K; Brooks C; Green AI; Brunette MF; Rosenthal RN; Dunn KE; Strain EC; Ray L; Shoptaw S; Ait-Daoud Tiouririne N; Gunderson EW; Ransom J; Scott C; Leggio L; Caras S; Mason BJ; Litten RZ;
    Alcohol Clin Exp Res; 2019 Jan; 43(1):158-169. PubMed ID: 30403402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.
    Anton RF; Latham P; Voronin K; Book S; Hoffman M; Prisciandaro J; Bristol E
    JAMA Intern Med; 2020 May; 180(5):728-736. PubMed ID: 32150232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of N-acetylcysteine and working memory training on glutamate concentrations in the dACC and rACC in regular cocaine users - A randomized proof of concept study.
    Schulte MHJ; Goudriaan AE; Boendermaker WJ; van den Brink W; Wiers RW
    Neurosci Lett; 2021 Sep; 762():136146. PubMed ID: 34332028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.
    White TL; Monnig MA; Walsh EG; Nitenson AZ; Harris AD; Cohen RA; Porges EC; Woods AJ; Lamb DG; Boyd CA; Fekir S
    Neuropsychopharmacology; 2018 Jun; 43(7):1498-1509. PubMed ID: 29511334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder.
    Pennington DL; Abé C; Batki SL; Meyerhoff DJ
    Psychiatry Res; 2014 Dec; 224(3):281-7. PubMed ID: 25444536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.
    Ray LA; Bujarski S; Shoptaw S; Roche DJ; Heinzerling K; Miotto K
    Neuropsychopharmacology; 2017 Aug; 42(9):1776-1788. PubMed ID: 28091532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study.
    Yang YS; Maddock RJ; Zhang H; Lee J; Hellemann G; Marder SR; Green MF
    Psychiatry Res Neuroimaging; 2022 Sep; 325():111515. PubMed ID: 35839558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal trajectories of anterior cingulate glutamate and subclinical psychotic experiences in early adolescence: the impact of bullying victimization.
    Okada N; Yahata N; Koshiyama D; Morita K; Sawada K; Kanata S; Fujikawa S; Sugimoto N; Toriyama R; Masaoka M; Koike S; Araki T; Kano Y; Endo K; Yamasaki S; Ando S; Nishida A; Hiraiwa-Hasegawa M; Edden RAE; Sawa A; Kasai K
    Mol Psychiatry; 2024 Apr; 29(4):939-950. PubMed ID: 38182806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for a unique association between fronto-cortical glycine levels and recent heavy drinking in treatment naïve individuals with alcohol use disorder.
    Prisciandaro JJ; Schacht JP; Prescot AP; Brenner HM; Renshaw PF; Brown TR; Anton RF
    Neurosci Lett; 2019 Jul; 706():207-210. PubMed ID: 31108129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Alcohol Cues on MRS Glutamate Levels in the Anterior Cingulate.
    Cheng H; Kellar D; Lake A; Finn P; Rebec GV; Dharmadhikari S; Dydak U; Newman S
    Alcohol Alcohol; 2018 May; 53(3):209-215. PubMed ID: 29329417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.
    Grant JE; Chamberlain SR; Redden SA; Leppink EW; Odlaug BL; Kim SW
    JAMA Psychiatry; 2016 May; 73(5):490-6. PubMed ID: 27007062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm.
    Spurny B; Vanicek T; Seiger R; Reed MB; Klöbl M; Ritter V; Unterholzner J; Godbersen GM; Silberbauer LR; Pacher D; Klug S; Konadu ME; Gryglewski G; Trattnig S; Bogner W; Lanzenberger R
    Neuroimage; 2021 May; 232():117913. PubMed ID: 33657450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics.
    Schacht JP; Anton RF; Randall PK; Li X; Henderson S; Myrick H
    Psychopharmacology (Berl); 2013 Jun; 227(4):627-37. PubMed ID: 23389755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does the change in glutamate to GABA ratio correlate with change in depression severity? A randomized, double-blind clinical trial.
    Narayan GA; Hill KR; Wengler K; He X; Wang J; Yang J; Parsey RV; DeLorenzo C
    Mol Psychiatry; 2022 Sep; 27(9):3833-3841. PubMed ID: 35982258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial.
    Burnette EM; Baskerville WA; Grodin EN; Ray LA
    Trials; 2020 Sep; 21(1):779. PubMed ID: 32912290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.